ARCHIVES

Also HHS Inspector General is reviewing Lester Crawford’s departure from FDA.

This article is from The Cancer Letter archive.

Vol. 31 No. 39 | October 28, 2005

Download PDF Visit The Full Archive

Related Articles

Broder’s Conundrum: How To Let Congress Know NCI Needs More Money Without Asking For it

March 17, 1989

FDA Grants Priority Review To Two Drugs in NSCLC

February 22, 2013

SEER Program Challenged, Will Face Review

May 9, 1980

House Overrides Veto Of Authorization Bill As GOP Members Join Democrats In Assailing Reagan Action

November 15, 1985

Drugs and Targets: Blincyto granted accelerated approval in R/R ALL

December 5, 2014

Anti-Estrogen Drug Therapy Reduces Risk of Invasive Breast Cancer In Older Women

July 25, 2008